DecisionView Launches StudyOptimizer 4
San Francisco, CA – December 10, 2009
DecisionView Inc., a provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer™ 4, the latest iteration of its Web-based solution. DecisionView’s flagship product now includes advanced historical analysis and templates capabilities, as well as enhancements to its predictive analytics technology.
StudyOptimizer allows clinical trial managers to plan, track, diagnose, and correct enrollment plans via a single centralized Web-based application that
captures clinical trial patient enrollment data from across the organization. The application uses predictive analytics to forecast enrollment trends and estimate completion dates, which are updated based on actual enrollment patterns giving clinical trial managers information to measure actual and projected performance against plan.
“The ability to capture, analyze, and leverage historical clinical trial enrollment data in planning future patient recruitment efforts provides a critical baseline that life sciences organizations need in order to benchmark and improve these processes,” said said Alan Louie, Ph.D., Research Director, IDC.
Recently, DecisionView announced the availability of the Software-as-a-Service (SaaS) version of StudyOptimizer.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
